title: Drug safety. Heart attack risk overshadows a popular diabetes therapy.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Couzin
mesh_terms: D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy; D004345:Drug Industry; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000139:chemically induced*; D012306:Risk; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014280:Triglycerides; D000077154:Rosiglitazone